The Latest Cardiac and Vascular News
Novel embolic device designed to obstruct or reduce blood flow, Funded by Strategic Investor. DENVER, Oct. 24, 2025 /PRNewswire/ — Polyembo, a privately held medical device company founded to develop the Scrunchy, Sphere, PuffyCoil, and other vascular embolization technologies, today…
ATLANTA, Oct. 23, 2025 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the market closes. On that day, the…
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast of the event will also be available on the “Investor Relations” section of the Heartflow website at https://ir.heartflow.com/. About Heartflow’s Technology and ResearchBacked by ACC/AHA guidelines and over 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for nearly 500,000 patients worldwide. Our continuous innovation is driven by an unmatched proprietary data pipeline built from over 110 million annotated CTA images. Heartflow’s AI-driven solutions have been extensively validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 96%. Heartflow’s integrated workflow delivers analysis instantly upon order, enabling clinicians to move from diagnosis to decision without delay. To uphold the highest security and patient-data integrity standards, Heartflow fully complies with leading global security regulations, including HITRUST, SOC2 Type 2, GDPR, HIPAA, CCPA, ISO 13485, and ISO 27001. About Heartflow, Inc.Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com. Investor ContactNick Laudiconlaudico@heartflow.com Media ContactElliot Levyelevy@heartflow.com
PARIS & BOSTON–(BUSINESS WIRE)–Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, today announced the appointment of Jonathan Freeman, PhD, as Chairman of its Board of Directors. This marks a key milestone in the company’s evolution, reinforcing its ambition to set new frontiers in the treatment of […]
MINNETONKA, Minn.–(BUSINESS WIRE)–AngioInsight, a leader in AI-powered cardiovascular diagnostics, today announced the appointment of Shlomi Nachman, former Worldwide Chairman of Johnson & Johnson’s Cardiovascular and Specialty Solutions (CSS), to its Board of Directors. AngioInsight is further announcing initiation of its Series A round of $25M, following the successful closing of its oversubscribed […]
-Financing supports execution of Phase 2b RAISE trial evaluating BB-031, an investigational reversible thrombolytic for acute ischemic stroke, and the planned Phase 1 study of BB-025, its fast-acting reversal agent- -Current CEO Richard Shea transitions to President and Chief Operating…
Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care Practices CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven Precision Cardiovascular Medicine company, today announced the Company has partnered with 15 new provider organizations across the United States. This expansion demonstrates the continued adoption of […]
October 20, 2025 PDF Version Proceeds Expected to Fund Ongoing Development and Submission Activities to Support FDA Evaluation of Company’s First and Next Generation Proprietary Ultralow Cryoablation Technologies LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Oct. 20, 2025– Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment […]
Nabeel Ahmed Named Chief Financial Officer; Mike Levitz and Bret Christensen Join Board of Directors LOS ANGELES, Oct. 20, 2025 /PRNewswire/ — Kandu, Inc., a healthcare technology company pioneering integrated stroke recovery solutions, today announced the appointment of Nabeel Ahmed as…
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025.
